All In Biotech

BLA 125469 · Eli Lilly and CO

Trulicity

Dulaglutide · Injection · GLP-1 Receptor Agonist

Novel

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 18, 2014

Approved uses

8

Original approval plus efficacy supplements

Registered trials

117

36 Phase 3, 10 recruiting

FAERS reports

89,369

23,531 serious, 1,706 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )] . TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum...

What it is approved for

From the label in effect Jun 16, 2026.

TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Mechanism: TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TRULICITY · DULAGLUTIDE 4.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
  • TRULICITY · DULAGLUTIDE 1.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
  • TRULICITY · DULAGLUTIDE 3MG/0.5ML · INJECTABLE, INJECTION · Prescription
  • TRULICITY · DULAGLUTIDE 0.75MG/0.5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dulaglutide" as an intervention, any sponsor and status, largest first.

All 117 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea10,580
  • injection site pain10,019
  • blood glucose increased9,960
  • diarrhoea6,200
  • vomiting5,949
  • incorrect dose administered5,663
  • inappropriate schedule of product administration3,843
  • drug ineffective3,757
  • weight decreased3,438
  • decreased appetite3,281
  • extra dose administered3,202
  • injection site haemorrhage3,179

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20124
201414
20151,678
20163,893
20176,225
20187,421
20199,334
202010,676
202112,619
202211,157
20239,512
20247,287
20255,875
20263,673

Recalls

2 FDA enforcement reports for this application.

  • Apr 5, 2022 · Class II · Completed

    TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions

  • Aug 19, 2021 · Class II · Terminated

    Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trulicity (Dulaglutide)

2024 spending

$5.45B

Beneficiaries

788,716

4,305,141 claims

Per beneficiary

$6,915

$467.75 per unit

View as table
YearSpending
2020$3,284,873,062
2021$4,702,174,724
2022$6,225,291,668
2023$7,363,856,224
2024$5,454,134,725

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 301 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.